If you follow the latest developments in obesity medicine, you have probably heard about retatrutide. The name has been circulating in medical circles, health forums and specialized media — and for good reason. Retatrutide may represent the most significant advance in obesity treatment since the arrival of semaglutide. But what exactly is it? How does it work? And what does it mean for you, in Canada, in 2025?

In this article, we explain everything you need to know about retatrutide — without unnecessary jargon, with up-to-date information.

What is Retatrutide?

Retatrutide (also known by its code LY3437943) is a synthetic peptide developed by Eli Lilly, the same laboratory that produced tirzepatide (Mounjaro). What makes retatrutide unique is that it simultaneously activates three different hormonal receptors: GLP-1, GIP, and glucagon. Hence its name: a “triple agonist.”

To understand why this matters, you first need to grasp what these three hormones do in your body.

The Role of GLP-1

GLP-1 (glucagon-like peptide-1) is an intestinal hormone released after meals. It signals the brain that you are full, slows gastric emptying, and stimulates insulin secretion in response to glucose. This is the mechanism that semaglutide (Ozempic, Wegovy) mimics — producing average weight losses of around 15% of body weight.

The Role of GIP

GIP (glucose-dependent insulinotropic polypeptide) amplifies the insulin response and plays a role in fat storage and release. Tirzepatide (Mounjaro) combines GLP-1 and GIP, delivering superior results compared to semaglutide alone — averaging 20 to 22% body weight loss.

The Role of Glucagon

In the context of retatrutide, activating the glucagon receptor produces two additional important effects: it increases basal energy expenditure (your body burns more calories at rest) and accelerates lipolysis — the breakdown of stored fat, especially visceral fat around the organs.

Clinical Results: What the Studies Actually Show

Phase 2 data published in the New England Journal of Medicine in 2023 stunned the medical community. Here is what they showed:

  • Participants receiving the highest dose (12 mg) lost an average of 24.2% of their body weight in just 48 weeks
  • Some individuals lost 30% or more
  • Visceral fat reduction was particularly pronounced
  • Glycemic improvements were significant in participants with type 2 diabetes

To put this in perspective: a 24% weight loss for a 220-pound person means losing over 50 pounds — without surgery. These results are comparable to bariatric surgery outcomes, historically considered the most effective treatment for severe obesity.

Side Effects Observed in Phase 2

Like other GLP-1 agonists, the most common side effects were gastrointestinal: nausea, vomiting, diarrhea and constipation, especially at the start of treatment and during dose escalation. These effects tend to diminish over time. No major safety signal was identified in phase 2 trials.

Where Are the Clinical Trials in 2025?

Eli Lilly has launched several phase 3 trials under the TRIUMPH program:

  • TRIUMPH-1: obese adults without type 2 diabetes
  • TRIUMPH-2: obese adults with type 2 diabetes
  • TRIUMPH-3: cardiovascular risk reduction
  • TRIUMPH-4: long-term weight maintenance after stopping treatment

Full results from these trials are expected between 2025 and 2026. If phase 3 data confirms phase 2 findings, an FDA approval application could follow as early as 2026, with Health Canada typically following within months.

Retatrutide in Canada: What to Expect

Retatrutide is not yet available in Canada outside of clinical trials. If you see websites claiming to sell it, exercise extreme caution — the molecule has not been validated for human use outside a controlled clinical setting.

That said, waiting does not mean doing nothing. Other validated peptide treatments available in Canada today can produce very significant results right now.

What Alternatives Are Available Today?

Semaglutide (Ozempic / Wegovy)

The most widely used GLP-1 agonist in Canada. Available as a weekly injection, it produces an average weight loss of 15% of body weight over 68 weeks in studies. Ozempic is approved for type 2 diabetes; Wegovy for obesity.

Tirzepatide (Mounjaro)

The dual GLP-1 and GIP agonist approved in Canada for type 2 diabetes under the name Mounjaro. Studies show weight loss superior to semaglutide, averaging 20 to 22% of body weight.

Who Will Retatrutide Be For?

Based on phase 2 data and trends observed with similar molecules, retatrutide will likely be indicated for:

  • Adults with a BMI ≥ 30
  • Adults with a BMI ≥ 27 associated with at least one weight-related comorbidity (diabetes, hypertension, sleep apnea, cardiovascular disease)
  • Individuals who have not achieved sufficient results with existing treatments

Frequently Asked Questions

Is retatrutide more effective than Ozempic?

Yes, based on available phase 2 data. Ozempic (semaglutide) produces an average 15% weight loss versus 24% for retatrutide at the highest dose. However, the two molecules have not been compared head-to-head in a clinical trial, so the comparison remains indirect.

Does retatrutide cause muscle loss?

As with all significant weight loss treatments, some loss may include lean mass. Phase 2 data suggests most loss is fat mass, but medical supervision and adequate protein intake remain essential.

Can I participate in a retatrutide clinical trial in Canada?

Trials are ongoing at select centers in Canada. Check your eligibility at ClinicalTrials.gov by searching “retatrutide.” Participation is free and medically supervised.

When will retatrutide be available in Canadian pharmacies?

If phase 3 trials conclude positively in 2025–2026, a Health Canada approval is conceivable around 2027. This is an estimate — regulatory timelines can vary.

What This Means for Obesity Medicine

Ten years ago, a 24% weight loss without surgery would have been considered impossible. Today, that is what the preliminary data for retatrutide suggests. It is not just about numbers on a scale — it is a revolution in how medicine understands and treats obesity: no longer as a failure of willpower, but as a chronic disease with effective medical solutions.

At Clinique Minceur, we follow these developments closely. Our goal is always to offer the best available options, tailored to each patient. If you want to explore what medicine can do for you today — or simply be informed when new options arrive — contact us for a consultation.